CY1123160T1 - Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης - Google Patents
Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησηςInfo
- Publication number
- CY1123160T1 CY1123160T1 CY20201100694T CY201100694T CY1123160T1 CY 1123160 T1 CY1123160 T1 CY 1123160T1 CY 20201100694 T CY20201100694 T CY 20201100694T CY 201100694 T CY201100694 T CY 201100694T CY 1123160 T1 CY1123160 T1 CY 1123160T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- beta cell
- antigen
- vitamin
- cell autoantigen
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 title 1
- 235000013922 glutamic acid Nutrition 0.000 title 1
- 239000004220 glutamic acid Substances 0.000 title 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 4
- 229930003316 Vitamin D Natural products 0.000 abstract 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 235000019166 vitamin D Nutrition 0.000 abstract 3
- 239000011710 vitamin D Substances 0.000 abstract 3
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 3
- 229940046008 vitamin d Drugs 0.000 abstract 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000003614 tolerogenic effect Effects 0.000 abstract 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 abstract 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01005—Acetolactate decarboxylase (4.1.1.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μέθοδο για πρόληψη και/ή αγωγή αυτοάνοσης πάθησης, περιλαμβάνουσα χορήγηση διατιθέμενης σύνθεσης, με την εν λόγω σύνθεση να περιλαμβάνει έστω ένα αυτοαντιγόνο βήτα κυττάρων, σε υποκείμενο. Το υποκείμενο είναι δυνατόν να έχει επίπεδο βιταμίνης-D ορού πάνω από 50 nanomole/λίτρο ή η σύνθεση είναι δυνατόν να χορηγηθεί μέσω ενδολεμφικής ένεσης ή ένεσης απευθείας σε λεμφαδένα, ή στην περίοδο εβδομάδων, μηνών ή ετών. Η εφεύρεση επίσης σχετίζεται με σύνθεση περιλαμβάνουσα πλήθος σωματιδίων, με έκαστο να φέρει ακινητοποιημένο πάνω στην επιφάνεια του τουλάχιστον ένα πρώτο και τουλάχιστον ένα δεύτερο αντιγόνο, όπου το πρώτο αντιγόνο είναι αυτοαντιγόνο βήτα κυττάρων, και το δεύτερο αντιγόνο είναι είτε ανεκτικογόνο ή αυτοαντιγόνο βήτα κυττάρων, και με σύνθεση περιλαμβάνουσα i) τουλάχιστον ένα αυτοαντιγόνο βήτα κυττάρων, και τουλάχιστον ένα από iia) IL-10 επάγουσα ένωση επιλεγόμενη από την ομάδα που αποτελείται από βιταμίνη-D, ανάλογα βιταμίνης-D, αναστολείς τυροσινοκινάσης, γαμμα-αμινοβουτυρικό οξύ, και ανάλογα γαμμα-αμινο βουτυρικού οξέος• και iib) ένωση η οποία μειώνει την ικανότητα των δενδριτικών κυττάρων να ενεργοποιούν αδαή CD4+ Τ κύτταρα, όπως αναστολέα κυκλοοξυγονάσης, CTLA-4 ένωση ή αναστολέα TNF άλφα. Η εφεύρεση επίσης σχετίζεται με φαρμακευτικά κιτ και με την ιατρική χρήση αυτοαντιγόνων βήτα κυττάρων.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450678 | 2014-06-04 | ||
| SE1451315 | 2014-11-04 | ||
| PCT/SE2015/050651 WO2015187087A2 (en) | 2014-06-04 | 2015-06-04 | Novel combinations for antigen based therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123160T1 true CY1123160T1 (el) | 2021-10-29 |
Family
ID=54767532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100694T CY1123160T1 (el) | 2014-06-04 | 2020-07-28 | Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20170196949A1 (el) |
| EP (2) | EP3760224A3 (el) |
| JP (2) | JP6686007B2 (el) |
| CN (2) | CN114504639A (el) |
| AU (3) | AU2015268960B2 (el) |
| CA (2) | CA2950893C (el) |
| CY (1) | CY1123160T1 (el) |
| DK (1) | DK3151853T3 (el) |
| ES (1) | ES2807787T3 (el) |
| HU (1) | HUE051151T2 (el) |
| IL (3) | IL300130B2 (el) |
| LT (1) | LT3151853T (el) |
| PL (1) | PL3151853T3 (el) |
| PT (1) | PT3151853T (el) |
| RS (1) | RS60581B1 (el) |
| RU (2) | RU2019129803A (el) |
| SI (1) | SI3151853T1 (el) |
| WO (1) | WO2015187087A2 (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6827113B2 (ja) | 2017-01-21 | 2021-02-10 | 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 |
| US20210077587A1 (en) * | 2017-09-08 | 2021-03-18 | Diamyd Medical Ab | Genotype stratification in diabetes treatment and prevention |
| US20210063392A1 (en) | 2017-09-08 | 2021-03-04 | Diamyd Medical Ab | Improved immunotherapy |
| WO2019151939A1 (en) * | 2018-02-05 | 2019-08-08 | Diamyd Medical Ab | Novel composition and use thereof |
| US11752156B2 (en) | 2018-03-07 | 2023-09-12 | Athenex HK Innovative Limited | Compositions and methods for treating hyperproliferative skin disorders |
| US10500217B2 (en) | 2018-04-30 | 2019-12-10 | Leslie Ray Matthews, M.D., Llc | Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases |
| US20220211813A1 (en) * | 2019-04-12 | 2022-07-07 | Loma Linda University | Methods for treatment of niemann-pick disease type c |
| US20240245762A1 (en) * | 2021-01-13 | 2024-07-25 | University Of Maryland, College Park | Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto |
| WO2022264088A1 (en) * | 2021-06-17 | 2022-12-22 | Phaim Pharma Ltd. | Individualized cell therapy using patient-derived antigen-specific regulatory t cells |
| WO2023066881A1 (en) * | 2021-10-18 | 2023-04-27 | Astrazeneca Ab | Inhibition of map3k15 for treating and preventing diabetes |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674978A (en) * | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
| JP2000500120A (ja) * | 1995-09-21 | 2000-01-11 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | ポリ（エチレングリコール）と抗グルタミン酸デカルボキシラーゼ抗体の結合体の膵島細胞指向ターゲット化 |
| SE9503379D0 (sv) * | 1995-09-29 | 1995-09-29 | Synectics Medical Ab | A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD |
| US6884785B2 (en) | 1999-06-17 | 2005-04-26 | The Scripps Research Institute | Compositions and methods for the treatment or prevention of autoimmune diabetes |
| EP2301553A1 (en) * | 2001-11-21 | 2011-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
| US20050152914A1 (en) * | 2003-06-13 | 2005-07-14 | Diamyd, Inc. | Formulation of antigen |
| EP1725254A4 (en) * | 2004-02-04 | 2008-02-13 | Univ Columbia | ANTI-CD3 AND ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF AUTOIMMUNITY |
| EP1755631A2 (en) * | 2004-03-03 | 2007-02-28 | Diamyd Medical AB | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes |
| WO2007044394A2 (en) * | 2005-10-05 | 2007-04-19 | Bayhill Therapeutics, Inc. | Compositions and methods for treatment of autoimmune disease |
| JP5694668B2 (ja) * | 2006-12-29 | 2015-04-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 自己免疫疾患の診断上および治療上の標的ならびにその用途 |
| AU2008240667A1 (en) * | 2007-04-24 | 2008-10-30 | Diamyd Therapeutics Ab | Medicaments and methods to treat autoimmune disease and cancer |
| MX350501B (es) * | 2007-10-12 | 2017-09-07 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| EP2219669A4 (en) * | 2007-12-19 | 2011-03-09 | Mivac Dev Aktiebolag | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND ALLERGIC DISEASES |
| WO2012050907A2 (en) * | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
| WO2012062697A1 (en) * | 2010-11-08 | 2012-05-18 | Novartis Ag | Combination therapy for type 1 diabetes |
| US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
-
2015
- 2015-06-04 RU RU2019129803A patent/RU2019129803A/ru unknown
- 2015-06-04 CA CA2950893A patent/CA2950893C/en active Active
- 2015-06-04 EP EP20172919.1A patent/EP3760224A3/en active Pending
- 2015-06-04 ES ES15802815T patent/ES2807787T3/es active Active
- 2015-06-04 US US15/315,557 patent/US20170196949A1/en not_active Abandoned
- 2015-06-04 RU RU2016150656A patent/RU2702632C2/ru active
- 2015-06-04 DK DK15802815.9T patent/DK3151853T3/da active
- 2015-06-04 JP JP2017516633A patent/JP6686007B2/ja active Active
- 2015-06-04 AU AU2015268960A patent/AU2015268960B2/en active Active
- 2015-06-04 LT LTEP15802815.9T patent/LT3151853T/lt unknown
- 2015-06-04 PT PT158028159T patent/PT3151853T/pt unknown
- 2015-06-04 HU HUE15802815A patent/HUE051151T2/hu unknown
- 2015-06-04 CN CN202210193065.7A patent/CN114504639A/zh active Pending
- 2015-06-04 CN CN201580040912.4A patent/CN106535926B/zh active Active
- 2015-06-04 WO PCT/SE2015/050651 patent/WO2015187087A2/en active Application Filing
- 2015-06-04 PL PL15802815T patent/PL3151853T3/pl unknown
- 2015-06-04 SI SI201531269T patent/SI3151853T1/sl unknown
- 2015-06-04 EP EP15802815.9A patent/EP3151853B1/en active Active
- 2015-06-04 IL IL300130A patent/IL300130B2/en unknown
- 2015-06-04 RS RS20200789A patent/RS60581B1/sr unknown
- 2015-06-04 CA CA3210184A patent/CA3210184A1/en active Pending
-
2016
- 2016-11-28 IL IL249250A patent/IL249250B/en active IP Right Grant
-
2020
- 2020-03-12 IL IL273265A patent/IL273265B2/en unknown
- 2020-04-01 JP JP2020066176A patent/JP2020125300A/ja active Pending
- 2020-05-15 AU AU2020203169A patent/AU2020203169B2/en active Active
- 2020-07-28 CY CY20201100694T patent/CY1123160T1/el unknown
-
2021
- 2021-08-26 US US17/458,018 patent/US20220000995A1/en active Pending
-
2022
- 2022-03-23 AU AU2022202003A patent/AU2022202003A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123160T1 (el) | Αποκαρβοξυλαση γλουταμικου οξεος (gad) για χρηση στην αγωγη αυτοανοσης παθησης | |
| Akha | Aging and the immune system: An overview | |
| Kim et al. | The transcription factor Ets1 suppresses T follicular helper type 2 cell differentiation to halt the onset of systemic lupus erythematosus | |
| Ma et al. | Serine is an essential metabolite for effector T cell expansion | |
| Yang et al. | ATF4 regulates CD4+ T cell immune responses through metabolic reprogramming | |
| Zanetti | A second chance for telomerase reverse transcriptase in anticancer immunotherapy | |
| CY1120622T1 (el) | Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii | |
| Hill et al. | Glycogen synthase kinase‐3 controls IL‐10 expression in CD4+ effector T‐cell subsets through epigenetic modification of the IL‐10 promoter | |
| Wang et al. | Adjuvant-specific regulation of long-term antibody responses by ZBTB20 | |
| Lim et al. | Increased Th17 differentiation in aged mice is significantly associated with high IL-1β level and low IL-2 expression | |
| CY1121258T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου | |
| Sonner et al. | The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas | |
| BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
| Ohradanova-Repic et al. | Extracellular purine metabolism is the switchboard of immunosuppressive macrophages and a novel target to treat diseases with macrophage imbalances | |
| Gao et al. | Synergy between IL-6 and TGF-β signaling promotes FOXP3 degradation | |
| EP3119913A2 (en) | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| Clouthier et al. | GITR intrinsically sustains early type 1 and late follicular helper CD4 T cell accumulation to control a chronic viral infection | |
| CO6612271A2 (es) | Anticuerpos anti-cd40 | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| Buskiewicz et al. | Sex hormone receptor expression in the immune system | |
| Yao et al. | Neutralization of interleukin‐9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses | |
| Newman et al. | Members of the novel UBASH3/STS/TULA family of cellular regulators suppress T‐cell‐driven inflammatory responses in vivo | |
| WO2015013508A2 (en) | Methods for diagnosing and treating immune disease |